Company Overview of Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology. It is developing fostamatinib, an oral spleen tyrosine kinase inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and in Phase II clinical trials for autoimmune hemolytic anemia and IgA nephropathy; R348, an ophthalmic janus kinase/spleen tyrosine kinase inhibitor that is in Phase II clinical trials for the treatment of patients with ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has li...
1180 Veterans Boulevard
South San Francisco, CA 94080
Founded in 1996
Key Executives for Rigel Pharmaceuticals, Inc.
Chief Executive Officer, President, Director and Member of Finance Committee
Total Annual Compensation: $600.0K
Co-Founder, President of Discovery & Research, Executive Vice President and Director
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $441.3K
Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary
Total Annual Compensation: $475.5K
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2015.
Rigel Pharmaceuticals, Inc. Key Developments
Rigel Pharmaceuticals, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 10:30 AM
Jun 2 16
Rigel Pharmaceuticals, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ryan D. Maynard, Chief Financial Officer and Executive Vice President.
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016
May 3 16
Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported contract revenues from collaborations of $5,029,000 compared to $2,178,000 a year ago. Loss from operations was $17,567,000 compared to $18,241,000 a year ago. Net loss was $17,464,000 or $0.19 per basic and diluted share compared to $18,193,000 or $0.21 per basic and diluted share a year ago.
Rigel Pharmaceuticals, Inc. to Report Q1, 2016 Results on May 03, 2016
Apr 26 16
Rigel Pharmaceuticals, Inc. announced that they will report Q1, 2016 results at 5:00 PM, Eastern Standard Time on May 03, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|